The first patient has been enrolled in Global Blood Therapeutics' (NASDAQ:GBT) Phase 3 clinical trial, HOPE, evaluating lead product candidate GBT440 in people with sickle cell disease (SCD) who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year. The primary endpoint is the proportion of participants who achieve more than a 1 g/dL increase in hemoglobin at week 24 compared to baseline.
GBT440 is an oral, once-daily therapy that works by increasing hemoglobin's affinity for oxygen. It is also in development for the treatment of hypoxemia in patients with ideopathic pulmonary fibrosis.
Shares are up a fraction after hours.
Subscribe for full text news in your inbox